The Delhi high court on Wednesday observed that an investigation initiated by the Competition Commission of India (CCI) against Roche Products (India) for abuse of dominant position was an ‘interference in the administration of justice’.
CCI had initiated investigation against Roche and held it to be abusing its position as a market leader resulting in denial of market access to other pharmaceutical companies.
The regulator’s order was based on written communications by Roche to authorities including the Director Controller General of India (DCGI), National Pharmaceutical Pricing Authority (NPPA) and hospitals/potential buyers discouraging them from buying biosimilar versions of its cancer drug, Trastuzumab sold by its competitors— Mylan and Biocon.
Full Content: Outlook India
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canadian Breadmakers Settle Price-Fixing Lawsuit
Jul 25, 2024 by
CPI
EssilorLuxottica Open to Meta as Shareholder, Says CEO Francesco Milleri
Jul 25, 2024 by
CPI
California Supreme Court Upholds Proposition 22, Securing Independent Contractor Status for Uber and Lyft Drivers
Jul 25, 2024 by
CPI
Paramount Global Investor Sues to Block Skydance Media Merger
Jul 25, 2024 by
CPI
Software Vendors Win Class Action Status in Antitrust Case Against CDK Global
Jul 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Trade & Antitrust
Jul 26, 2024 by
CPI
What is Wrong with the WTO Discipline on Subsidies?
Jul 26, 2024 by
CPI
The Abiding Tension Between Trade Remedy Law and Antitrust
Jul 26, 2024 by
CPI
Trade and Antitrust: An End to Isolationism
Jul 26, 2024 by
CPI
International Trade Law and Domestic Regulation of Generative Artificial Intelligence: Divergent Approaches?
Jul 26, 2024 by
CPI